Stryker Corporation (NYSE:SYK) insider Lonny J. Carpenter sold 5,000 shares of Stryker Corporation stock in a transaction on Friday, August 4th. The stock was sold at an average price of $146.36, for a total value of $731,800.00. Following the transaction, the insider now directly owns 88,207 shares of the company’s stock, valued at approximately $12,909,976.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of Stryker Corporation (NYSE SYK) traded up 0.10% on Monday, reaching $146.67. The company had a trading volume of 466,809 shares. Stryker Corporation has a 12 month low of $106.48 and a 12 month high of $148.84. The company’s 50-day moving average is $142.76 and its 200 day moving average is $134.44. The firm has a market capitalization of $54.86 billion, a PE ratio of 32.74 and a beta of 0.80.
Stryker Corporation (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, topping the Zacks’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The company had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.98 billion. During the same quarter last year, the company earned $1.39 EPS. The company’s quarterly revenue was up 6.1% on a year-over-year basis. Equities analysts forecast that Stryker Corporation will post $6.50 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be given a $0.425 dividend. The ex-dividend date is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.16%. Stryker Corporation’s dividend payout ratio is currently 37.95%.
Several research analysts have recently issued reports on SYK shares. Deutsche Bank AG reaffirmed a “buy” rating and set a $148.00 price target (up previously from $135.00) on shares of Stryker Corporation in a research note on Saturday, April 29th. BidaskClub downgraded Stryker Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Zacks Investment Research raised Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 price target for the company in a research note on Monday, July 17th. Stifel Nicolaus lifted their price target on Stryker Corporation from $151.00 to $158.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $160.00 price target (up previously from $150.00) on shares of Stryker Corporation in a research note on Sunday, July 30th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Stryker Corporation has an average rating of “Hold” and an average price target of $144.03.
Hedge funds have recently made changes to their positions in the company. Bollard Group LLC increased its stake in shares of Stryker Corporation by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock worth $109,000 after buying an additional 3 shares in the last quarter. Baystate Wealth Management LLC increased its position in Stryker Corporation by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock valued at $139,000 after buying an additional 22 shares during the period. James Investment Research Inc. bought a new position in Stryker Corporation during the second quarter valued at approximately $155,000. Guardian Life Insurance Co. of America increased its position in Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock valued at $158,000 after buying an additional 9 shares during the period. Finally, Assetmark Inc. increased its position in Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock valued at $168,000 after buying an additional 4 shares during the period. Institutional investors own 73.99% of the company’s stock.